CardioSource (8/14, 2K)
reports that, according to the researchers, “The advantages associated with
early surgical correction of mitral valve regurgitation were confirmed in both
unmatched and matched populations, using multiple statistical methods.”
MedPage Today (8/14,
Phend, 185K) reports that “repair within 3 months of diagnosis in absence of
traditional class I indications was associated with roughly half the mortality
risk of watchful waiting, for 10-year survival rates of 86% versus 69%
(P<0 .001="" 10="" 23="" absence="" also="" and="" any="" at="" atrial="" benefits="" class="" come="" developed="" didn="" early="" even="" extra="" failure="" fewer="" fibrillation="" for="" found="" heart="" held="" i="" in="" investigators="" o:p="" of="" overall.="" p="" patients="" risk="" substantially="" surgery="" t="" that="" the="" these="" traditional="" triggers="" versus="" with="" years="">0>
Heartwire (8/14,
O'Riordan, 5K) points out that “the American College of Cardiology/American
Heart Association (ACC/AHA) guidelines for the treatment of MR state that
surgery is a class I indication for symptomatic patients or those with an
ejection fraction <60 diameter="" end-systolic="" left="" or="">40 mm.” 60>
HealthDay (8/14,
Thompson, 2K) also covers the story
No comments:
Post a Comment